1. Introduction {#sec1-cancers-12-01564}
===============

Breast cancer (BC) is the most common cancer and the leading cause of death by cancer in women in France and around the world \[[@B1-cancers-12-01564]\]. In France, the incidence of BC for women under 40 years of age is increasing with an average annual variation of +0.9 \[[@B2-cancers-12-01564]\]. Concurrently, this increase in incidence is associated with a decrease in mortality, with an average annual variation of −1.6 \[[@B2-cancers-12-01564]\]. Survival after BC varies from one country to another \[[@B3-cancers-12-01564]\], with the highest survival rate (87%) being observed in France, from 2005 to 2010, compared to other European countries \[[@B4-cancers-12-01564],[@B5-cancers-12-01564]\]. Improved survival raises the question of improved living conditions for survivors. In this regard, increasing attention has been focused on health-related quality of life (HRQoL) \[[@B6-cancers-12-01564]\] in recent decades, as well as on issues related to fertility and socio-professional reintegration, particularly among young women. Indeed, cancer is affecting increasing numbers of working individuals, who have a long professional life ahead of them. A return to work is generally perceived by this population as important for recovery \[[@B7-cancers-12-01564]\]. Therefore, it is necessary to focus on the professional reintegration of young women who have had a BC. Moreover, Meneses et al. reported that difficulties linked to maternity and fertility were the main factors hindering HRQoL in young BC survivors, due to the side effects of treatment, such as chemotherapy, on ovarian function \[[@B8-cancers-12-01564]\]. The sexuality of women with BC can also be perturbed, for both physical and psychological reasons. To the best of our knowledge, few population-based studies have encompassed all these post-cancer issues among young women with BC in France.

Using data from the specialized Côte d'Or Breast and Gynaecologic Cancer Registry, this study aimed to identify the clinical, social and economic determinants of HRQoL among young BC survivors. Secondarily, we describe the living conditions of BC survivors, with regard to fertility, sexual function, psychological distress and professional reinsertion.

2. Materials and Methods {#sec2-cancers-12-01564}
========================

2.1. Patients {#sec2dot1-cancers-12-01564}
-------------

This cross-sectional study was conducted using data from the specialized Breast and Gynaecologic Cancer Registry of the Côte d'Or Department in France, the only registry in France to focus on breast and gynecological cancers. The registry catchment area has approximately 500,000 inhabitants, of whom 270,000 are women. The population is predominantly rural, with low migration. The registry has been collecting comprehensive population-based data at the time of diagnosis for all cases of breast and gynecological cancer occurring in Côte d'Or residents since 1982. The Côte-d'Or is one of the eight French departments in the region of Burgundy Franche-Comté, in northeast France. Its prefecture, Dijon, is also the regional capital. The department's economic activity is 70% tertiary, 25% industry and 5% agriculture. Previous studies have been published using data from the French Côte d'Or Breast and Gynaecologic Cancer Registry \[[@B9-cancers-12-01564],[@B10-cancers-12-01564]\]. Female BC survivors, aged 45 and younger at the time of diagnosis, diagnosed with non-metastatic BC between 1st January 2006 and 31st December 2015 were identified. Patients who died or relapsed before January 2019 were excluded. In February 2019, eligible participants were sent a study information pack by post that included an information letter, the study questionnaires and a stamped return envelope. Patient's referring physicians were provided with information about the study and were informed that their patients would be approached for participation. For patients who did not respond within one month, a reminder was sent.

Ethics approval: this study was performed in accordance with the declaration of Helsinki. The study was approved by the French national data protection authority (CNIL-MR003 N°1989764-v0) and by the Committee for the Protection of Persons South-East I (2018-A03431-54).

2.2. Outcomes, Measures, Study Variables {#sec2dot2-cancers-12-01564}
----------------------------------------

### 2.2.1. Outcome Variables {#sec2dot2dot1-cancers-12-01564}

The main outcome of this study was HRQoL, as assessed by the validated Medical Outcome Study 12-item Short Form health survey questionnaire (SF-12) \[[@B11-cancers-12-01564],[@B12-cancers-12-01564]\]. Through its 12 items, this questionnaire generates eight scales: physical functioning, role physical, bodily pain, role emotional, vitality, social functioning, mental health and general health. All scales were scored according to the standard scoring method of the SF-12 scoring manual. Each score ranges from 0 to 100, with higher scores representing a better level of HRQoL.

### 2.2.2. Predictor Variables {#sec2dot2dot2-cancers-12-01564}

The Hospital Anxiety and Depression Scale (HADS) questionnaire, validated and adapted in French by Lepine et al. \[[@B13-cancers-12-01564]\] was used to detect anxiety and depressive disorders. This scale has 14 items (7 each for anxiety and depression), all rated from 0 to 3. Total scores range from 0 to 21, and a subscale score of 11 or more indicates presence of anxiety or depression.

Social support was assessed by Sarason's social support questionnaire (SSQ6), validated and adapted in French by Rascle et al. \[[@B14-cancers-12-01564]\]. This 6-item questionnaire measures the availability of social support and the satisfaction with the perceived support. Availability scores range from 0 to 54, and satisfaction scores range from 6 to 36. A higher satisfaction score represents better perceived social support. Scores were categorized into 2 classes, using the respective median value.

Socio-economic deprivation was assessed using the French Evaluation de le Précarité et des Inégalités de santé pour les Centres d'Examen de Santé (EPICES) \[[@B15-cancers-12-01564]\]. This questionnaire, developed specially for the French context, contains 11 items that take into account the overall living conditions and generate an overall deprivation score. Scores vary from 0 to 100, and allow classification of patients as deprived or not deprived (\>30 and ≤30, respectively).

The Female Sexual Function Index (FSFI) is a self-administrated questionnaire specific to sexual function in women. It was developed by Raymond Rosen and has been validated in French \[[@B16-cancers-12-01564],[@B17-cancers-12-01564]\]. Through its 19 items, it explores six scales (desire, excitement, lubrication, orgasm, satisfaction and pain) of sexual function. Global score ranges from 2 to 36; an overall score \<26.5 indicates sexual dysfunction. For each scale, a score \<3.9 is considered as a deterioration on that scale.

Fertility concerns after BC were assessed using a specific questionnaire, developed in conjunction with clinicians and surgeons. Data collected included the number of pregnancies before and after diagnosis, information on treatment effects and fertility preservation before treatment, fertility preservation techniques, adoption, number of abortions and number of spontaneous miscarriages after treatment end.

Professional reinsertion was assessed using another study-specific questionnaire developed in conjunction with sociologists and psychologists. Data collected were problems obtaining loans, income since diagnosis, ability to work (after treatment and at the time of survey), impact of cancer and perceived discrimination in professional life.

Patient and tumor characteristics, including age at diagnosis (categorized as ≤35 and \>35 years), age at the time of the survey (categorized as ≤45 and \>45 years), Charlson's comorbidity index, tumor stage, tumor grade, hormone status, human epidermal growth factor receptor 2 (HER2) status and treatments were extracted from the Côte d'Or Breast and Gynaecologic Cancer Registry database. Time since diagnosis was categorized in two classes according to the median (≤86 and \>86 months). body mass index (BMI) was classified as underweight and normal weight (BMI ≤25 kg/m^2^) and overweight (BMI \>25 kg/m^2^). Tumor stage was categorized according to the 8th edition of the Tumor Nodes Metastasis (TNM)-American Joint Commission of Cancer (AJCC) classification \[[@B18-cancers-12-01564]\].

### 2.2.3. Statistical Analysis {#sec2dot2dot3-cancers-12-01564}

We compared clinical characteristics and treatments between respondents and non-respondents using the chi-square or Fischer's exact test for categorical variables and the Mann-Whitney test for continuous variables. HRQoL, anxiety and depression, social support, deprivation and sexual function scores were generated, categorized and described, in addition to the other quantitative variables as mean (standard deviation, SD) or median (range). Clinical and social characteristics, treatment and all qualitative variables are described as number and percentage.

A mixed regression model was built to identify the determinants of the 8 domains of HRQoL. The variables eligible for multivariate analysis were those with a *p* value \< 0.10 by univariate analysis (for the eight dimensions of SF-12). Correlations and interactions were tested for eligible variables. Results are reported as multivariate analysis coefficients, SDs and *p* values.

Bonferroni's correction was used to adjust the α-risk in the eight multivariate models (α' = α/n with n corresponding to the number of comparisons made). The significance level for the multivariate analyses was therefore set at *p* \< 0.00625.

All analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-cancers-12-01564}
==========

Four hundred and thirty-one patients with BC were eligible for this study. For 23 of these, the return address was no longer in use. The questionnaire was thus mailed to 408 participants, of whom 218 completed the questionnaire (response rate 53.4%). The details are shown in [Figure 1](#cancers-12-01564-f001){ref-type="fig"}.

Respondents and non-respondents did not differ significantly in terms of clinical characteristics or treatments: age at diagnosis (*p* = 0.0490); age at time of survey (*p* = 0.1015); time since diagnosis (*p* = 0.7607); AJCC stage (*p* = 0.2673); tumor grade (*p* = 0.3391); hormone receptor status (*p* = 0.1408); HER2 status (*p* = 0.5709); tumor triple negative status (*p* = 0.2479); menopausal status at diagnosis (*p* = 0.8060); Charlson comorbidity index (*p* = 0.2336); chemotherapy (*p* = 0.1477); radiotherapy (*p* = 0.4795); endocrine therapy (*p* = 0.5772). The details of comparisons between respondents and non-respondents are shown in [Table S1](#app1-cancers-12-01564){ref-type="app"}.

3.1. Demographic and Clinical Characteristics of Participants {#sec3dot1-cancers-12-01564}
-------------------------------------------------------------

Mean age of study participants was 40.1 (SD = 4.4) years at the time of diagnosis and 47.4 (SD = 5.1) at the time of the survey. Mean BMI was 24.3 (SD = 4.5). Median time since diagnosis was 86 months (range, 36--155). At the time of diagnosis, 90.3% of women were married or living maritally. This proportion decreased to 60.9% at the time of survey. Other main characteristics were AJCC stage 1 (42%), no comorbidities (90%), menopaused at time of survey (53%), no deprivation (81%) and employed at the time of the survey (87%). All patients underwent surgery and the majority were treated by chemotherapy (77%), radiotherapy (85%) and endocrine therapy (71%). The demographic and clinical characteristics of the participants are shown in [Table 1](#cancers-12-01564-t001){ref-type="table"}.

3.2. HRQoL, Sexual Function, Social Support, Anxiety and Depression Scores {#sec3dot2-cancers-12-01564}
--------------------------------------------------------------------------

### 3.2.1. HRQoL Scores {#sec3dot2dot1-cancers-12-01564}

The highest average score was in the physical functioning scale (80.8), and the lowest was in vitality (50.7). There were less than 3% of missing values in each of SF-12 dimensions (see [Table 2](#cancers-12-01564-t002){ref-type="table"}).

### 3.2.2. Sexual Function Scores {#sec3dot2dot2-cancers-12-01564}

Mean global FSFI score was 22.1 (SD = 10.5). Using the threshold of 26.5 to define the presence of sexual dysfunction, approximately 55% of women reported sexual dysfunction. Moreover, a deterioration was seen for each subscale (desire, arousal, pain, lubrication, orgasm), except satisfaction (see [Table 2](#cancers-12-01564-t002){ref-type="table"}).

### 3.2.3. Social Support Scores {#sec3dot2dot3-cancers-12-01564}

The median social support availability score was 19 (range, 0--54) and the median social support satisfaction score was 31 (range, 6--36) (see [Table 2](#cancers-12-01564-t002){ref-type="table"}). A higher social support satisfaction score represents better perceived social support.

### 3.2.4. Anxiety and Depression Scores {#sec3dot2dot4-cancers-12-01564}

Using the threshold of 11 to define the presence of mood disorders, 29% of women had anxiety, and less than 10% had depression (see [Table 2](#cancers-12-01564-t002){ref-type="table"}).

3.3. Determinants of HRQoL {#sec3dot3-cancers-12-01564}
--------------------------

Significant determinants of HRQoL in young women with BC are shown in [Table 3](#cancers-12-01564-t003){ref-type="table"}. By multivariate analysis, depression was found to be a significant independent determinant of general health (β = 17.34; *p* = 0.0006), physical functioning (β = 20.34; *p* = 0.0028), role physical (β = 24.75; *p* = 0.0008), vitality (β = 29.22; *p* \< 0.0001), role emotional (β = 32.62; *p* \< 0.0001), mental health (β = 18.57; *p* \< 0.0001) and social functioning (β = 26.67; *p* \< 0.0001). Patients with anxiety were more likely to have bodily pain (β = 13.40; *p* = 0.0015), limitations due to emotional state (β = 20.03; *p* \< 0.0001), poor mental health (β = 19.52; *p* \< 0.0001) and poor social functioning (β = 15.90; *p* \< 0.0001). Social support satisfaction was associated with general health (β = 7.30; *p* = 0.0042) and social functioning (β = 11.31; *p* = 0.0005). Women menopaused at time of survey were more likely to have deteriorated general health (β = 7.19; *p* = 0.0051). Deprivation was significantly associated with bodily pain (β = 13.44; *p* = 0.0037) and mental health (β = 9.40; *p* = 0.0013). Women with no comorbidities at the time of diagnosis were more likely to have better physical functioning (β = 6.03; *p* = 0.0055).

3.4. Fertility Data and Concerns {#sec3dot4-cancers-12-01564}
--------------------------------

Before treatment, 65.1% of women had regular menstrual cycles. This rate decreased significantly after treatment to 17%. Forty-nine (22.8%) women had no menstrual cycles before treatment, and this increased to 121 (57.1%) after treatment. Seventy women (33%) reported that they did not receive information before treatment about the impact of cancer treatment on fertility and ovarian function, and 150 (72%) reported that they did not receive information about fertility preservation. Among these, 55 (38%) would have liked to have been informed.

Eighty-five percent of the study participants already had children at the time of diagnosis. Twenty-one (9.8%) had a pregnancy project at time of diagnosis and 66 women (33.2%) gave up a pregnancy project after the diagnosis. Three out of these 21 women had a medically assisted procreation (MAP) consultation before treatment, of whom two agreed with the proposed fertility preservation and one woman became pregnant with MAP after treatment. Two of these 21 women had a spontaneous pregnancy after treatment. The fertility data of the study population are shown in [Table 4](#cancers-12-01564-t004){ref-type="table"}.

3.5. Professional Reinsertion {#sec3dot5-cancers-12-01564}
-----------------------------

The full details of professional reinsertion are shown in [Table 5](#cancers-12-01564-t005){ref-type="table"}. Sixty women (27%) declared that their income had decreased since diagnosis, and 154 (70%) patients had a bank loan in progress. Among 62 women who had sought a home loan since diagnosis, 47 (81%) reported difficulties (exclusion and/or increased insurance premium and refusal) with insurance. Eighty-two women (38%) reported a negative impact of cancer on their professional life and 160 women (73%) reported a decreased ability to work after treatment and at the time of the survey (59%). The main reason for the reduced ability to work was fatigue in 84% of women at the end of treatment, and 75% at the time of the survey. Thirty-seven percent of women reported the occurrence of one of the following events: retirement, stopped working, made redundant, bankruptcy, sale or cessation of an independent professional activity, resignation, different position and transfer within the same company; among whom 60% specified that the events occurred due to BC.

4. Discussion {#sec4-cancers-12-01564}
=============

This population-based study assessed the medical and socioeconomic determinants of HRQoL among young women with BC identified through the French Côte d'Or Breast and Gynaecologic Cancer Registry. One of the main strengths of this study was the use of a specialized registry database, which has the advantage of being representative of regionally treated patients, enabling us to assess long-term HRQoL. We also used validated instruments to assess HRQoL and psychological outcomes. Moreover, this study encompassed all aspects of post-cancer life in young women with BC (HRQoL, fertility, sexuality, professional reintegration).

The response rate (53.4%) in this survey was similar to that of previous population-based studies in this geographical area \[[@B19-cancers-12-01564],[@B20-cancers-12-01564],[@B21-cancers-12-01564]\]. Indeed, Chu et al. and Dialla et al. reported a response rate of 59% and 62%, respectively, in studies including women of all ages at diagnosis of BC \[[@B20-cancers-12-01564],[@B21-cancers-12-01564]\]. There was no significant difference between respondents and non-respondents in terms of clinical characteristics and treatments in our study, and therefore, no potential selection bias in our results.

The limitations of this study included the cross-sectional design. Indeed, the time since diagnosis ranged from 36 to 155 months in our study, with a median time since diagnosis of 86 months. This raises concerns about recall bias, given the questions about fertility and return to work events at diagnosis or during the time of treatment.

Our results showed that anxiety, depression, social support satisfaction, deprivation, comorbidities and menopause were significant determinants of HRQoL for long-term young BC survivors, as may also be the case in a population of young women without BC \[[@B22-cancers-12-01564],[@B23-cancers-12-01564],[@B24-cancers-12-01564],[@B25-cancers-12-01564]\].

In this study, approximately half of the women had sexual dysfunction. Cobo-Cuenca et al. and Abril-Requena et al. also found similar results in a population of Spanish women with BC \[[@B26-cancers-12-01564],[@B27-cancers-12-01564]\]. Sexual function is an important component of HRQoL among BC survivors. The effects of BC on sexuality depend on treatment, disease severity and how patients experienced their relationship and sexuality before cancer \[[@B28-cancers-12-01564],[@B29-cancers-12-01564]\].

In our study, the participants reported disturbed menstrual cycles after treatment. This could be attributable to the side effects of BC treatment on ovarian function, such as adjuvant chemotherapy \[[@B8-cancers-12-01564]\]. Jacobson et al. reported similar results in a population of women with BC treated by chemotherapy with or without radiotherapy in the United States \[[@B30-cancers-12-01564]\]. We noted that among women who did not receive information about fertility preservation, more than a third would have liked to have been informed. This underlines the unmet need for fertility preservation information among this age group, as shown by our study. Young women need access to high-quality health information to support their involvement in medical decision-making concerning fertility preservation \[[@B31-cancers-12-01564],[@B32-cancers-12-01564],[@B33-cancers-12-01564]\]. These results may be useful for clinical practice, in terms of counseling on fertility preservation as part of BC treatment. The very low rate of access to fertility preservation observed in our study should be interpreted in light of the period of diagnosis. Today, fertility preservation is accessible to larger numbers. Few women became pregnant after treatment in our study. Anderson et al. found that the chance of achieving a first pregnancy was lower for women \>5 years after diagnosis of all cancer types, with a marked reduction in women with BC \[[@B34-cancers-12-01564]\]. Nevertheless, we cannot rule out the possibility that the low number of pregnancies after treatment may also depend on the structure of the questionnaire used or some unexplored specificity of the population under study. Indeed, in our study, few women were interested in having children after diagnosis, and for that reason, the number of pregnancies and miscarriages were indeed very low.

Another important finding was that for half of the women in our study, their income was unchanged since the BC diagnosis. Saito et al. found a lower rate than in the present study \[[@B35-cancers-12-01564]\]. One explanation could be that approximately 50% of our sample had a higher level of education. However, Jensen et al. found that, overall, after seven years, BC did not have any effect on income but the negative effect of BC on income lasted longer among women with a higher educational level \[[@B36-cancers-12-01564]\]. In our study, about one-third of women with BC reported a negative impact of BC on their professional life. These results are consistent with previous studies on the influence of cancer on work-related issues among Japanese BC survivors aged 20 years and older and Korean BC survivors at working age \[[@B35-cancers-12-01564],[@B37-cancers-12-01564]\]. The women in our study also reported a decreased ability to work after treatment, as well as difficulties obtaining loans. In women with BC, the main reason for the impaired ability to work was fatigue, both before (84%) and after treatment (75%). One explanation for this reduced ability to work due to fatigue in women with BC might be the treatment strategies \[[@B38-cancers-12-01564]\]. Abrahams et al. found that cancer-related fatigue was reported in up to 90% of persons with cancer during adjuvant treatment \[[@B39-cancers-12-01564]\]. Moreover, Jones et al. reported the persistence of fatigue up to 6 years post-treatment in approximately one-third of cancer survivors \[[@B40-cancers-12-01564]\].

5. Conclusions {#sec5-cancers-12-01564}
==============

In conclusion, the results of this study show that the main determinants of HRQoL in long-term young BC survivors are anxiety, depression, social deprivation, social support satisfaction and menopausal status. Other main issues highlighted by this study are the negative impact of BC on professional reintegration and sexual function, the unmet need for information about the impact of cancer treatment on fertility, and for information about fertility preservation. Specific interventions in this population should therefore focus on the promotion of professional reintegration and information about the impact of cancer treatment on fertility, as well as fertility preservation.

We thank Isabel Grégoire and Fiona Ecarnot for English language checking and Marie-Laure Poillot for data collection.

The following are available online at <https://www.mdpi.com/2072-6694/12/6/1564/s1>, Table S1: Comparison of clinical characteristics between respondents and non-respondents.
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cancers-12-01564-t001_Table 1

###### 

Demographic and clinical characteristics of the study population (N = 218).

  Characteristics                       No. of Patients   Median (Min--Max)   \%
  ------------------------------------- ----------------- ------------------- ------
  Age at diagnosis, years                                                     
  ≤35                                   27                                    12.4
  \>35                                  191                                   87.6
  Age at time of survey, years                                                
  ≤45                                   60                                    27.5
  \>45                                  158                                   72.5
  BMI at time of survey                                                       
  ≤25                                   134                                   62.0
  \>25                                  82                                    38.0
  Missing data                          2                                     
  Marital status at time of survey                                            
  Married/living maritally              132                                   60.6
  Single/divorced/widowed               86                                    39.4
  Missing data                          0                                     
  Educational level                                                           
  Less than high school diploma         57                                    26.5
  High school diploma or higher         158                                   73.5
  Missing data                          3                                     
  Employment at time of survey                                                
  Employed                              189                                   87.5
  Unemployed                            27                                    12.5
  Missing data                          2                                     
  Time since diagnosis, months                                                
  Mean                                                    87.7                
  Median (min-max)                      218               86 (36--155)        
  SD                                                      34.2                
  Time since diagnosis, months                                                
  ≤86                                   110                                   50.5
  \>86                                  108                                   49.5
  AJCC stage                                                                  
  1                                     93                                    42.7
  2/3                                   125                                   57.3
  Missing data                          0                                     
  Tumor grade                                                                 
  I                                     41                                    19.6
  II                                    92                                    44.0
  III                                   76                                    36.4
  Missing data                          9                                     
  Hormone Receptor status                                                     
  Positive                              166                                   76.5
  Negative                              51                                    23.5
  Missing data                          1                                     
  HER2 status                                                                 
  Positive                              47                                    21.8
  Negative                              169                                   78.2
  Missing data                          2                                     
  Triple negative status                                                      
  Yes                                   37                                    17.1
  No                                    179                                   82.9
  Missing data                          2                                     
  Menopausal status at time of survey                                         
  Menopausal                            112                                   53.6
  Non-menopausal                        97                                    46.4
  Missing data                          9                                     
  Charlson comorbidity Index                                                  
  =0                                    195                                   90.3
  ≥1                                    21                                    9.7
  Missing data                          2                                     
  Surgery                                                                     100
  Yes                                   216                                   
  No                                    0                                     
  Missing data                          2                                     
  Chemotherapy                                                                
  Yes                                   168                                   77.4
  No                                    49                                    22.6
  Missing data                          1                                     
  Radiotherapy                                                                
  Yes                                   186                                   85.7
  No                                    31                                    14.3
  Missing data                          1                                     
  Endocrine therapy                                                           
  Yes                                   156                                   71.9
  No                                    61                                    28.1
  Missing data                          1                                     
  EPICES deprivation score ^a^          213                                   
  Mean                                                    17.3                
  Median \[min-max\]                                      13.6 (0--75.7)      
  SD                                                      17.2                
  Missing data                          5                                     
  EPICES deprivation score ^a^                                                
  EPICES ≤ 30                           174                                   81.7
  EPICES \> 30                          39                                    18.3
  Missing data                          5                                     

^a^: Scores range from 0 to 100 and classify patients as deprived or not deprived (\>30 and ≤30, respectively). BMI: body mass index. HER2: human epidermal growth factor receptor 2. AJCC: American Joint Commission of Cancer.

cancers-12-01564-t002_Table 2

###### 

Health-related quality of life (HRQoL), sexual function, social support, anxiety and depression scores in the study population (N = 218).

  Dimensions                                     No. of Patients   Mean (SD)     Median (Min-Max)
  ---------------------------------------------- ----------------- ------------- ------------------
  **Health-Related Quality of Life: SF12 ^a^**                                   
  General health                                 217               67.3 (19.1)   60 (25--100)
  Physical functioning                           217               80.8 (27.1)   100 (0--100)
  Role physical                                  216               68.3 (28.2)   75 (0--100)
  Role emotional                                 217               67.8 (26.6)   75 (0--100)
  Bodily pain                                    217               75.0 (27.3)   75 (0--100)
  Mental health                                  217               59.9 (19.6)   62.5 (0--100)
  Vitality                                       217               50.7 (24.6)   50 (0--100)
  Social functioning                             215               68.5 (25.8)   75 (0--100)
  **Sexual function ^b^**                                                        
  Desire                                         215               3 (1.3)       3 (1.2--6)
  Arousal                                        213               3.2 (1.9)     3.6 (0--6)
  Pain                                           211               3.6 (2.4)     4.4 (0--6)
  Satisfaction                                   194               4.2 (1.7)     4.4 (0.8--6)
  Lubrication                                    215               3.5 (2.3)     4.2 (0--6)
  Orgasm                                         211               3.4 (2.2)     4 (0--6)
  Global Score                                   188               22.1 (10.5)   25.1 (2--36)
  Sexual dysfunction (%)                                                         
  Yes                                            104 (55.3)                      
  No                                             84 (44.7)                       
  Missing data                                   30                              
  **Social support ^c^**                                                         
  Social support availability                    212               20.5 (11.2)   19 (0--54)
  Social support satisfaction                    196               28.8 (7.9)    31 (6--36)
  Social support availability (%)                                                
  \<19                                           102 (48.1)                      
  ≥19                                            110 (51.9)                      
  Missing data                                   6                               
  Social support satisfaction (%)                                                
  \<31                                           97 (49.5)                       
  ≥31                                            99 (50.5)                       
  Missing data                                   22                              
  **HADS ^d^**                                                                   
  Anxiety                                        216               8.7 (3.8)     8 (2--20)
  Depression                                     217               4.7 (3.6)     4 (0--16)
  Anxiety                                                                        
  \<11                                           153 (70.8)                      
  ≥11                                            63 (29.1)                       
  Missing data                                   2                               
  Depression                                                                     
  \<11                                           198 (91.2)                      
  Dimensions                                     No. of Patients   Mean (SD)     Median (Min-Max)
  ≥11                                            19 (8.8)                        
  Missing data                                   1                               

^a^: Scores range from 0 to 100 with higher scores representing better HRQoL. ^b^: Global score ranges from 2 to 36; an overall score \<26.5 corresponds to sexual dysfunction. For each scale, a score \<3.9 is considered as an alteration on that scale. ^c^: Availability scores range from 0 to 54 and satisfaction scores range from 6 to 36. A higher social support satisfaction score represents better perceived social support. ^d^: Both the anxiety and depression subscores range from 0 to 21, with a score of 11 or higher indicating the probable presence of mood disorder.
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###### 

Significant determinants of health-related quality of life.

  Scales Scores of the SF-12 and Variables   Estimate   Standard Error   *p*-Value
  ------------------------------------------ ---------- ---------------- -----------
  **General health ^a^**                                                 
  Depression                                                             0.0006
  \<11/≥11                                   17.34      4.99             
  Social support satisfaction                                            0.0042
  ≥31/\<31                                   7.30       2.52             
  Menopausal status at time of survey                                    0.0051
  No/Yes                                     7.19       2.53             
  **Physical functioning ^b^**                                           
  Depression                                                             0.0028
  \<11/≥11                                   20.34      6.70             
  Scales scores of the SF-12 and variables   Estimate   Standard error   *p*-value
  Charlson's comorbidity score                                           0.0055
  =0/≥1                                      6.03       4.02             
  **Role physical ^c^**                                                  
  Depression                                                             0.0008
  \<11/≥11                                   24.75      7.23             
  **Role emotional ^d^**                                                 
  Anxiety                                                                \<0.0001
  \<11/≥11                                   20.03      3.63             
  Depression                                                             \<0.0001
  \<11/≥11                                   32.62      6.26             
  **Bodily pain ^e^**                                                    
  Anxiety                                                                0.0015
  \<11/≥11                                   13.40      4.15             
  EPICES deprivation score                                               0.0037
  ≤30/\>30                                   13.44      6.96             
  **Mental health ^f^**                                                  
  Anxiety                                                                \<0.0001
  \<11/≥11                                   19.52      2.58             
  Depression                                                             \<0.0001
  \<11/≥11                                   18.57      4.04             
  EPICES deprivation score                                               0.0013
  ≤30/\>30                                   9.40       2.87             
  **Vitality ^g^**                                                       
  Depression                                                             \<0.0001
  \<11/≥11                                   29.22      5.82             
  **Social functioning ^h^**                                             
  Anxiety                                                                \<0.0001
  \<11/≥11                                   15.90      3.74             
  Depression                                                             \<0.0001
  \<11/≥11                                   26.67      6.25             
  Social support satisfaction                                            0.0005
  ≥31/\<31                                   11.31      3.21             

Mixed models regression (Significant at *p*-value \< 0.00625) ^a^: Adjusted for anxiety, Evaluation de le Précarité et des Inégalités de santé pour les Centres d'Examen de Santé (EPICES) deprivation score, social support availability, Charlson's comorbidity score at diagnosis. ^b^: Adjusted for age at the time of diagnosis, time since diagnosis, body mass index (BMI), anxiety, EPICES deprivation score, social support availability, tumor stage, hormonal status, menopausal status at the time of the survey. ^c^: Adjusted for anxiety, EPICES deprivation score, social support availability, social support satisfaction, Charlson's comorbidity score at diagnosis, menopausal status at time of survey. ^d^: Adjusted for time since diagnosis, EPICES deprivation score, social support satisfaction, radiotherapy, menopausal status at the time of the survey. ^e^: Adjusted for time since diagnosis, depression, social support availability, social support satisfaction, marital status at the time of diagnosis, tumor stage. ^f^: Adjusted for time since diagnosis, social support availability. ^g^: Adjusted for time since diagnosis, anxiety, EPICES deprivation score, social support availability, menopausal status at the time of the survey. ^h^: Adjusted for time since diagnosis, EPICES deprivation score, social support availability.
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###### 

Fertility data of the study population.

  Variables                                                                                             No. of Patients   \%
  ----------------------------------------------------------------------------------------------------- ----------------- ------
  Contraception at time of diagnosis                                                                                      
  No                                                                                                    44                20.9
  Yes                                                                                                   167               79.2
  Missing data                                                                                          7                 
  Menstrual cycle before treatment                                                                                        
  Non-existent                                                                                          49                22.8
  Regular                                                                                               140               65.1
  Irregular                                                                                             26                12.1
  Missing data                                                                                          3                 
  Menstrual cycle after treatment                                                                                         
  Non-existent                                                                                          121               57.1
  Regular                                                                                               36                17.0
  Irregular                                                                                             55                25.9
  Missing data                                                                                          6                 
  Children at the time of diagnosis                                                                                       
  No                                                                                                    32                14.8
  Yes                                                                                                   184               85.2
  Missing data                                                                                          2                 
  Pregnancy project at time of diagnosis                                                                                  
  No                                                                                                    194               90.2
  Yes                                                                                                   21                9.8
  Missing data                                                                                          3                 
  Gave up a pregnancy project after treatment                                                                             
  Yes                                                                                                   66                33.2
  No                                                                                                    133               66.8
  Missing data                                                                                          19                
  Planned pregnancy project after treatment                                                                               
  Yes                                                                                                   15                7.3
  No                                                                                                    190               92.7
  Missing data                                                                                          13                
  Children at time of diagnosis among women who had pregnancy project at time of diagnosis (*n* = 21)                     
  No                                                                                                    7                 33.3
  Yes                                                                                                   14                66.7
  Spontaneous pregnancy before diagnosis (*n* = 14)                                                                       
  No                                                                                                    1                 7.1
  Yes                                                                                                   13                92.9
  Pregnancy with MAP before diagnosis (*n* = 14)                                                                          
  0                                                                                                     7                 77.8
  1                                                                                                     2                 22.2
  Missing data                                                                                          5                 
  Information received about impact of treatment on fertility and ovarian function                                        
  Yes                                                                                                   70                33.8
  No                                                                                                    68                32.9
  I forgot                                                                                              69                33.3
  Missing data                                                                                          11                
  Fertility preservation-related information                                                                              
  Yes                                                                                                   56                27.2
  No                                                                                                    150               72.8
  Missing data                                                                                          12                
  Would have liked to be informed if fertility preservation-related information not given (*n* = 150)                     
  Yes                                                                                                   55                38.7
  No                                                                                                    87                61.3
  Missing data                                                                                          8                 
  MAP Consultation (*n* = 21)                                                                                             
  No                                                                                                    16                84.2
  Yes                                                                                                   3                 15.8
  Missing data                                                                                          2                 
  Fertility preservation proposed if MAP consultation ^a^ (*n* = 3)                                                       
  No                                                                                                    0                 
  Yes                                                                                                   3                 100
  Agreed to proposed fertility preservation (*n* = 3)                                                                     
  No                                                                                                    1                 66.7
  Yes                                                                                                   2                 33.3
  Spontaneous pregnancy after treatment (*n* = 21)                                                                        
  0                                                                                                     13                86.7
  1                                                                                                     2                 13.3
  Missing data                                                                                          6                 
  Pregnancy with MAP after treatment (*n* = 21)                                                                           
  0                                                                                                     13                92.9
  1                                                                                                     1                 7.1
  Missing data                                                                                          7                 
  Adoption (*n* = 21)                                                                                                     
  Yes                                                                                                   1                 5.3
  No                                                                                                    18                94.7
  Missing data                                                                                          2                 
  Abortion since cancer (*n* = 21)                                                                                        
  Yes                                                                                                   0                 
  No                                                                                                    20                100
  Missing data                                                                                          1                 
  Spontaneous miscarriages (*n* = 21)                                                                                     
  Yes                                                                                                   1                 5.0
  No                                                                                                    19                95.0
  Missing data                                                                                          1                 

^a^: MAP: Medically Assisted Procreation.
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###### 

Professional outcomes in the study population.

  Variables                                                                         No. of Patients   \%
  --------------------------------------------------------------------------------- ----------------- ------
  Income since cancer diagnosis                                                                       
  Increased                                                                         43                19.8
  Unchanged                                                                         114               52.5
  Decreased                                                                         60                27.7
  Missing data                                                                      1                 
  Bank loan in progress                                                                               
  No                                                                                64                29.4
  Yes                                                                               154               70.6
  Difficulties repaying bank loans in progress                                                        
  No                                                                                139               64.9
  Yes                                                                               28                13.1
  Not concerned                                                                     47                22.0
  Missing data                                                                      4                 
  Asked for a loan since treatment                                                                    
  No                                                                                94                45.2
  Yes                                                                               114               54.8
  Missing data                                                                      10                
  Answer to a home loan request (*n* = 61) ^a^                                                        
  Agreement without conditions                                                      10                17.5
  Difficulties with insurance (refusal, exclusions and/or increased premium)        47                82.5
  Missing data                                                                      4                 
  Employment at time of diagnosis                                                                     
  Employed                                                                          183               84.3
  Unemployed                                                                        34                15.7
  Missing data                                                                      1                 
  Arduous working conditions at time of diagnosis                                                     
  Yes                                                                               91                46.2
  No                                                                                106               53.8
  Missing data                                                                      21                
  Decreased ability to work after the end of treatment                                                
  Yes                                                                               160               73.4
  No                                                                                53                24.3
  Not concerned                                                                     5                 2.3
  Reasons for decreased ability to work after the end of treatment                                    
  Fatigue                                                                           135               84.4
  Pain                                                                              69                43.1
  Limitation of some of my movements                                                69                43.1
  Limitation of my cognitive abilities                                              80                50.0
  Emotional problems                                                                58                36.3
  Other symptoms                                                                    10                6.3
  Decreased ability to work at the time of survey                                                     
  Yes                                                                               128               59.0
  No                                                                                85                39.2
  Not concerned                                                                     4                 1.8
  Missing data                                                                      1                 
  Reasons for decreased ability to work at the time of the survey                                     
  Fatigue                                                                           96                75.0
  Pain                                                                              53                41.4
  Limitation of some of my movements                                                51                39.8
  Limitation of my cognitive abilities                                              54                42.2
  Emotional problems                                                                39                30.5
  Other symptoms                                                                    4                 3.1
  Impact of cancer on work                                                                            
  Positive                                                                          45                21.2
  Negative                                                                          82                38.7
  None                                                                              85                40.1
  Missing                                                                           6                 
  Perceived discrimination                                                                            
  Yes                                                                               61                28.4
  No                                                                                123               57.2
  Not applicable                                                                    31                14.4
  Missing data                                                                      3                 
  Events since the end of treatment                                                                   
  Retirement, stopped working                                                       1                 0.5
  Made redundant                                                                    22                10.8
  Bankruptcy, sale or cessation of an independent activity                          6                 3.0
  Resignation                                                                       11                5.4
  Different position, transfer (within the same company)                            36                17.7
  None                                                                              127               62.6
  Missing data                                                                      15                
  Role of cancer or its after-effects in the aforementioned events (*n* = 76) ^b^                     
  No                                                                                30                39.5
  Yes                                                                               46                60.5
  Missing data                                                                                        

^a^: patients who had had estate loan ^b^: patients who had had at least one of the aforementioned events.
